Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02648464
Other study ID # 2015-000233-73
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date February 1, 2016
Est. completion date December 31, 2019

Study information

Verified date June 2020
Source Helsinki University Central Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This safety pilot study evaluates the effect of hydroxychloroquine on preventing recurrent cardiovascular events among myocardial infarction patients. Half of the participants will receive hydroxychloroquine, whereas the other half will receive placebo during six months.


Description:

Anti-rheumatic medications decrease cardiovascular mortality in rheumatoid arthritis patients, based mainly on their anti-inflammatory effect. No studies have addressed their effect on preventing recurrent cardiovascular events among non-rheumatic patients.

In the pilot phase 200 myocardial infarction patients will be recruited during their index visit to the study hospitals. Patients will be randomized after initial coronary angiography to receive either hydroxychloroquine 300 mg a day or placebo during six months. Patients will be followed up until 12 months at four visits. Visit one is at doctor´s office at 3 to 5 weeks from the day of recruitment. Visit two is at study nurse´s office at 5.5 to 6 months. Visit three is a phone interview by the study nurse at 8.5 to 9.5 months. Visit four at 11.5 to 12.5 months is at doctor´s office.

This study evaluates the safety of hydroxychloroquine in the setting of myocardial infarction, and whether hydroxychloroquine treatment could reduce the incidence of recurrent cardiovascular events among myocardial infarction patients. Furthermore, the effect of hydroxychloroquine on cardiovascular risk factors and systemic inflammation parameters will be studied. In a subgroup of 40 patients, the effect of hydroxychloroquine on aortic inflammation will be assessed by PET/CT scan.

If this safety pilot study with 200 patients proves successful (i.e. no major complications), 2500 patients will be recruited in additional centers in Finland and the Nordic Countries.

Orion Pharma provides the active hydroxychloroquine tablet (Oxiklorin) but provides no other assistance or funding for the study.


Recruitment information / eligibility

Status Completed
Enrollment 125
Est. completion date December 31, 2019
Est. primary completion date December 31, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

Patients must have high-sensitivity troponin or CKMB above the upper limit of normal with at least one of the following criteria:

1. Anginal symptoms suggestive of cardiac ischemia

1. Accelerating pattern of anginal pain (episodes of angina that have at least 5 minutes duration and are more frequent, severe, longer in duration and/or precipitated by less exertion).

2. Prolonged (>20 minutes) or recurrent anginal pain at rest or with minimal effort.

3. Anginal pain at rest or with minimal exertion, and at least 20 minutes of duration, occurring >48 hours after an acute Q-wave myocardial infarction.

2. ECG criteria

1. New, persistent or transient ST-segment depression >0,1 mV (0,08 seconds after the J-point) in at least 2 extremity leads or 3 precordial leads.

2. New, persistent or transient ST-segment elevation in two contiguous leads =0.2 mV in men or =0.15 mV in women in leads V2-V3, and/or =0.1 mV in other leads.

Patients will be enrolled within 96 hours of coronary angiography

Exclusion Criteria:

- Contraindication for hydroxychloroquine (porphyria, psoriasis, retinopathy, hypersensitivity)

- Rheumatoid arthritis or other rheumatic disease

- Significant neuropathy of any cause

- Cardiomyopathy (diagnosed before the onset of index hospitalization)

- Muscle disease (that could worsen by the use of hydroxychloroquine)

- Pregnant or nursing women, and women of childbearing potential without efficient contraceptives.

- Angina precipitated by obvious provoking factors

- Prolonged ECG's corrected QT interval (>480 ms)

- Ongoing antibiotic therapy of any duration

- Uncontrolled severe cardiac arrhythmia resulting in hemodynamic instability

- Severe hepatic failure (alanine transaminase or gamma-glutamyltransferase =2 times above normal limits or international normalized ratio (INR) >1,5 and patient not using warfarin, and due to other than cardiac reasons).

- Renal failure, glomerular filtration rate <50 ml/min/1,73m2

- Hemoglobin <100 g/l (if not possible to correct with transfusion)

- Planned percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG)

- Index myocardial infarction due to PCI or CABG restenosis.

- Inability to interpret ST-T segment changes on ECG (e.g. complete left bundle branch block or paced rhythm)

- Prior thrombolytic therapy (within 12 hours)

- Inability to give informed consent

- Fulminant vomiting or other disability to give oral medication

- Over 80 years of age

- Life expectancy less than one year

- Receiving another investigational drug within 4 weeks prior to the study. (Patients who have participated in investigational trials before the 4-week time period may be randomized as long as they have reached the primary endpoint).

- Patients with any other medical condition which, in the investigator's opinion, would interfere with optimal participation in the study or produce a significant risk to the patient

In addition, patients are not eligible for the PET/CT subgroup if they have received statin-therapy in the last 2 months prior to the hospitalization (i.e. statin therapy started during the index hospitalization is not an exclusion criteria).

Study Design


Intervention

Drug:
Hydroxychloroquine

Placebo


Locations

Country Name City State
Finland Helsinki University Central Hospital Helsinki
Finland North Karelia Central Hospital Joensuu
Finland Kymenlaakso Central Hospital Kotka
Finland Päijät-Häme Central Hospital Lahti
Finland South Karelia Central Hospital Lappeenranta
Finland South Ostrobotnia Central Hospital Seinäjoki

Sponsors (5)

Lead Sponsor Collaborator
Helsinki University Central Hospital Aarne Koskelo Foundation, Finnish Cultural Foundation, Finnish Foundation for Cardiovascular Research, Orion Corporation, Orion Pharma

Country where clinical trial is conducted

Finland, 

References & Publications (1)

Hartman O, Kovanen PT, Lehtonen J, Eklund KK, Sinisalo J. Hydroxychloroquine for the prevention of recurrent cardiovascular events in myocardial infarction patients: rationale and design of the OXI trial. Eur Heart J Cardiovasc Pharmacother. 2017 Apr 1;3(2):92-97. doi: 10.1093/ehjcvp/pvw035. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Rate of major cardiovascular adverse events Myocardial infarction, mortality, hospitalization for unstable angina, and heart failure Twelve months
Secondary Rate of the primary endpoint plus stroke and urgent coronary revascularization Twelve months
Secondary Effect on the incidence of type 2 diabetes and the level of Hba1c Six months
Secondary Effect on cholesterol levels The effect of hydroxychloroquine on total cholesterol, low-density lipoprotein, high-density lipoprotein, and triglyceride levels Six months
Secondary Effect on high-sensitivity C-reactive protein (hs-CRP) level Six months
Secondary Effect on soluble biomarkers of inflammation Frozen samples (plasma and whole blood) will be stored for future evaluation of biomarkers related to inflammation and cardiovascular disease, such as tumor necrosis factor alpha, interleukin 6 (IL-6), IL-1beta, IL-18, and messenger ribonucleic acid (mRNA) analyses. Six months
Secondary Effect on aortic inflammation assessed by PET / CT scan Six months
See also
  Status Clinical Trial Phase
Recruiting NCT05654272 - Development of CIRC Technologies
Recruiting NCT05650307 - CV Imaging of Metabolic Interventions
Recruiting NCT04515303 - Digital Intervention Participation in DASH
Completed NCT04056208 - Pistachios Blood Sugar Control, Heart and Gut Health Phase 2
Recruiting NCT04417387 - The Genetics and Vascular Health Check Study (GENVASC) Aims to Help Determine Whether Gathering Genetic Information Can Improve the Prediction of Risk of Coronary Artery Disease (CAD)
Not yet recruiting NCT06211361 - Cardiac Rehabilitation Program in Patients With Cardiovascular Disease N/A
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT04514445 - The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches.
Enrolling by invitation NCT04253054 - Chinese Multi-provincial Cohort Study-Beijing Project
Completed NCT03273972 - INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers N/A
Completed NCT03680638 - The Effect of Antioxidants on Skin Blood Flow During Local Heating Phase 1
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Completed NCT04083872 - Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers(Fasting) Phase 1
Completed NCT04083846 - Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed) Phase 1
Completed NCT03619148 - The Incidence of Respiratory Symptoms Associated With the Use of HFNO N/A
Completed NCT03693365 - Fluid Responsiveness Tested by the Effective Pulmonary Blood Flow During a Positive End-expiratory Trial
Completed NCT03466333 - Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia Phase 2
Completed NCT04082585 - Total Health Improvement Program Research Project
Completed NCT05132998 - Impact of a Comprehensive Cardiac Rehabilitation Program Framework Among High Cardiovascular Risk Cancer Survivors N/A
Completed NCT05067114 - Solutions for Atrial Fibrillation Edvocacy (SAFE)